- Replimune will again submit its melanoma drug for approvalThird time’s the charm? Replimune announced Friday that it will submit its advanced melanoma drug RP1 for FDA review after two prior rejections. It said it has had new discussions with ...Endpoints · 1mo ago↗ source
- Agios ends development of tebapivat in low-risk MDS following subpar resultsAgios Pharmaceuticals has said it will stop developing its rare blood disorder drug for certain patients with myelodysplastic syndromes (MDS) due to disappointing Phase 2b data. The biotech’s pyr…Endpoints · 1mo ago↗ source
- #ASCO26: Bristol Myers details Phase 3 trial win for Pomalyst successorBristol Myers Squibb’s next-gen multiple myeloma drug cut the risk of disease progression or death for certain patients by 52% when added on top of a combination treatment regimen. The New Jersey…